Mesoblast (MESO) Competitors

Mesoblast (NASDAQ:MESO) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and community ranking.

Does the media prefer MESO or TGTX?

In the previous week, TG Therapeutics had 7 more articles in the media than Mesoblast. MarketBeat recorded 13 mentions for TG Therapeutics and 6 mentions for Mesoblast. TG Therapeutics' average media sentiment score of 0.77 beat Mesoblast's score of 0.68 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer MESO or TGTX?

TG Therapeutics received 247 more outperform votes than Mesoblast when rated by MarketBeat users. Likewise, 76.73% of users gave TG Therapeutics an outperform vote while only 70.27% of users gave Mesoblast an outperform vote.

Company	Underperform	Outperform
Mesoblast	Outperform Votes 409 70.27%	Underperform Votes 173 29.73%
TG Therapeutics	Outperform Votes 656 76.73%	Underperform Votes 199 23.27%

Which has higher valuation & earnings, MESO or TGTX?

TG Therapeutics has higher revenue and earnings than Mesoblast.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$5.90M	194.30	-$87.96M	N/A	N/A
TG Therapeutics	$233.66M	19.68	$12.67M	-$0.10	-295.37

Do analysts recommend MESO or TGTX?

Mesoblast presently has a consensus target price of $11.50, suggesting a potential upside of 14.54%. TG Therapeutics has a consensus target price of $37.67, suggesting a potential upside of 27.51%. Given TG Therapeutics' higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
TG Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Do institutionals and insiders believe in MESO or TGTX?

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 10.5% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more volatility & risk, MESO or TGTX?

Mesoblast has a beta of 3.47, meaning that its stock price is 247% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500.

Is MESO or TGTX more profitable?

Mesoblast has a net margin of 0.00% compared to TG Therapeutics' net margin of -5.42%. Mesoblast's return on equity of 0.00% beat TG Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
TG Therapeutics	-5.42%	-8.32%	-3.40%

Summary

TG Therapeutics beats Mesoblast on 9 of the 16 factors compared between the two stocks.